שולי רווח נקי Seres Therapeutics, Inc (MCRB)

לוגו גרפי של Seres Therapeutics (MCRB)

Seres Therapeutics (MCRB) growth is driven by the expansion of the drug Vowst and licensing payments. The company's sales margin history on the GURU.Markets chart confirms this trend, where this metric equals -2209.60. The external environment is shaped by strict ESG standards for wastewater treatment and the brand's high authority among physicians treating gastrointestinal infections.

שולי מכירות של החברה Seres Therapeutics (MCRB): לתקופה 04.07.2022 - 20.11.2026

פילוחים אנליטיים של חברת Seres Therapeutics

- שווי שוק ותחזית יעד של אנליסטים:
אנליטיקה מסכמת של החברה:Seres Therapeutics, Inc - MCRB
סחורת הדגל של Seres

An investment audit of Seres Therapeutics (MCRB) requires an analysis of the net margin, calculated as the ratio of net income to total revenue, to evaluate the efficiency of converting revenue into capital. The net profit margin trend reflects the ability of the proprietary Vowst platform to monetize unique treatment protocols, confirming the financial stability of the microbiome therapy biotech ecosystem.